(2-chloro-benzyl)-(2-pyrrolidin-1-yl-ethyl)-amine | 823188-88-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2-chloro-benzyl)-(2-pyrrolidin-1-yl-ethyl)-amine
• 英文别名: N-[(2-chlorophenyl)methyl]-2-pyrrolidin-1-ylethanamine
• CAS: 823188-88-1
• 化学式: C₁₃H₁₉ClN₂
• mdl: MFCD06011636
• 分子量: 238.76
• InChiKey: LOAGYWOUYSOKAJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  silica gel 、 3-(异丁烯酰氧)丙基三甲氧基硅烷 在 1,1-二苯基-2-苦味酰肼 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 6.0h， 生成 (2-chloro-benzyl)-(2-pyrrolidin-1-yl-ethyl)-amine
  参考文献：
  名称：

  SEPARATING AGENT FOR OPTICAL ISOMER AND METHOD FOR PREPARATION THEREOF

  摘要：

  公开号：

  EP1498404B1

文献信息

• [EN] CXCR7 RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR DE CXCR7
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2014191929A1

  公开（公告）日：2014-12-04

  The present invention relates to derivatives of formula (I) Formula (I) wherein (R1)n, R 2a, R 2b, R 3a, R 3b, R 4, L1, L2, X, Y and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.

  本发明涉及公式（I）的衍生物 公式（I）其中（R1）n，R 2a，R 2b，R 3a，R 3b，R 4，L1，L2，X，Y 和 Ar1 如描述中所述，其制备方法，其药学上可接受的盐，以及其作为药物的用途，含有一个或多个公式（I）化合物的药物组合物，特别是其作为CXCR7受体调节剂的用途。
• [EN] CXCR7 RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR CXCR7
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2016087370A1

  公开（公告）日：2016-06-09

  The present invention relates to derivatives of formula (I) wherein (R1)n, ring (A), Y1, Y2, X, R4, L1, L2, and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.

  本发明涉及式（I）的衍生物，其中（R1）n、环（A）、Y1、Y2、X、R4、L1、L2 和 Ar1 如描述中所述，以及其制备、其药学上可接受的盐，以及其作为药物的用途，包括含有一个或多个式（I）化合物的药物组合物，特别是其作为CXCR7受体调节剂的用途。
• CXCR7 RECEPTOR MODULATORS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US20160107997A1

  公开（公告）日：2016-04-21

  The present invention relates to derivatives of formula (I) wherein (R 1 ) n , R 2a , R 2b , R 3a , R 3b , R 4 , L 1 , L 2 , X, Y and Ar 1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.

  本发明涉及公式（I）的衍生物，其中（R1）n，R2a，R2b，R3a，R3b，R4，L1，L2，X，Y和Ar1如描述中所述，其制备方法，其制备的药学上可接受的盐，以及它们作为药物的用途，包括含有一个或多个公式（I）化合物的药物组合物，尤其是它们作为CXCR7受体调节剂的用途。
• CXCR7 receptor modulators
  申请人：IDORSIA PHARMACEUTICALS LTD

  公开号：US10202368B2

  公开（公告）日：2019-02-12

  The present invention relates to derivatives of formula (I) wherein (R1)n, ring (A), Y1, Y2, X, R4, L1, L2, and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.

  本发明涉及式 (I) 的衍生物 其中 (R1)n、环 (A)、Y1、Y2、X、R4、L1、L2 和 Ar1 如描述中所述；本发明涉及它们的制备、它们的药学上可接受的盐、它们作为药物的用途、含有一种或多种式 (I) 化合物的药物组合物，特别是它们作为 CXCR7 受体调节剂的用途。
• CXCR7 RECEPTOR MODULATORS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US20170327493A1

  公开（公告）日：2017-11-16

  The present invention relates to derivatives of formula (I) wherein (R 1 ) n , ring (A), Y 1 , Y 2 , X, R 4 , L 1 , L 2 , and A 1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.